IPhone App for Doctors to View Medical Scans is First Cleared by U.S. FDA

A mobile medical-imaging application won approval from U.S. regulators to let doctors examine pictures from patient scans on Apple Inc.’s iPhone and iPad.

The technology, known as Mobile MIM, is the first portable- device application for common medical images cleared by the Food and Drug Administration, the agency said today in a statement. The uses are for computerized tomography, magnetic resonance imaging and positron emission tomography scans.

The application, made by closely held MIM Software Inc. in Cleveland, enables hospitals and doctors’ offices to send images to physicians’ mobile devices over a secure network. The software isn’t intended to replace full workstations, and should only be used when a doctor doesn’t have access to the larger equipment, the FDA said.

“This important mobile technology provides physicians with the ability to immediately view images and make diagnoses without having to be back at the workstation or wait for film,” William Maisel, chief scientist and deputy director for science at the FDA’s Center for Devices and Radiological Health, said in the statement.

Mobile MIM should be available in Apple’s U.S. App Store next week, the Cleveland-based company said today on its website. The application is available in more than 30 countries including Australia, the U.K. and Hong Kong.

The iPhone, Apple’s biggest-selling product, accounted for 39 percent of the Cupertino, California-based company’s $26.7 billion in revenue for the quarter ended Dec. 25. Sales of the iPad, the world’s best selling tablet computer, comprised 17 percent of revenue. The company has sold more than 15 million iPads since its introduction in April.

To contact the reporter on this story: Molly Peterson in Washington at mpeterson9@bloomberg.net

To contact the editors responsible for this story: Adriel Bettelheim at abettelheim@bloomberg.net; Reg Gale in New York at rgale5@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.